Alzamend Neuro and Massachusetts General Hospital Launch Phase II Trial for Novel MDD Treatment
Alzamend Neuro partners with Massachusetts General Hospital to conduct a Phase II clinical trial of AL001, a next-generation lithium-based therapeutic for Major Depressive Disorder. This collaboration aims to develop a safer and more effective alternative to current lithium treatments.
Read the full story



























